Study summary
A blood-vessel-blocking pill slowed but did not shrink adenoid cystic carcinoma
45%progression-free at 6 months
What was tested
Regorafenib, a multi-target kinase inhibitor pill, for recurrent or metastatic adenoid cystic carcinoma.
What they found
- No tumors shrank by the response criteria; 45% were progression-free at 6 months.
- Tumors with more immune cells did better, and NOTCH1 changes predicted worse outcomes.
What it means
Shows why adenoid cystic carcinoma needs new approaches; NOTCH and immune-based strategies are being explored.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.